Report
Valens Research

ALGN - Embedded Expectations Analysis - 2019 05 29

Align Technology, Inc. (ALGN:USA) currently trades near historical highs relative to
UAFRS-based (Uniform) Earnings, with a 46.2x Uniform P/E, implying bullish expectations for the firm. However, management may have concerns about their ability to protect intellectual property and increase Invisalign sales in Latin America, and about orthodontic and GP dentist channel growth.

Specifically, management may be concerned about their digital solutions for tooth movement and scanning, the success of their Invisalign social media campaign, and their ability to protect intellectual property. Moreover, they may lack confidence in their ability to continue EMEA expansion, maintain gross margins, and sustain growth in their orthodontic and GP dentist channels. Also, they may be exaggerating their ability to grow Invisalign in Latin America, lead a transformation of digital orthodontics and dentistry, and grow the number of Invisalign cases submitted digitally.
Underlying
Align Technology Inc.

Align Technology is a medical device company engaged in the design, manufacture and marketing of Invisalign? clear aligners and iTero? intraoral scanners and services for orthodontics, restorative and aesthetic dentistry. The company's segments are: Clear Aligner, which includes the Invisalign System, a method for treating malocclusion based on a proprietary computer-simulated virtual treatment plan and a series of doctor-prescribed, custom manufactured, clear plastic, removable aligners; and Scanners and Services, which includes Intraoral scanning that enables the dental practitioner to create a 3D image of the patient's teeth (digital scan) using a handheld intraoral scanner.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch